Clinical trial

Rosuvastatin and Losartan Pharmacokinetics After Bariatric Surgery

Opening soon · Not applicable · 1 countries · Registry ID NCT07748273

Opening soonNot applicableInterventional

What this study is about

This prospective, open-label, non-randomized pharmacokinetic study will evaluate how Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy affect systemic exposure to single oral test doses of rosuvastatin and losartan. Sixty adults scheduled for bariatric surgery will enter one of two parallel groups according to the clinically selected operation (30 RYGB and 30 sleeve gastrectomy). Each participant will receive rosuvastatin 10 mg and losartan 25 mg once within 30 days before surgery and again approximately 12 weeks after surgery. Plasma samples collected before dosing and at 1.5 and 4 hours after dosing will be used with maximum a posteriori Bayesian estimation to estimate individual pharmacokinetic parameters. In the 30-participant RYGB group only, paired stool samples will be used to explore gut microbiota and untargeted fecal metabolomic changes. The primary objective is to compare within-participant changes and between-procedure differences in drug exposure after bariatric surgery.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to 65 Years

SexAll

Healthy volunteersNot accepted

ConditionObesity & Overweight, Bariatric Surgery, Pharmacokinetics After Oral Intake, Drug Absorption

Full registry criteria

Inclusion Criteria: * Adults aged 18 to 65 years; * Formal clinical indication for RYGB or sleeve gastrectomy after multidisciplinary assessment; * Bariatric surgery scheduled and no previous bariatric procedure; * Able to understand the study and provide written informed consent. Exclusion Criteria: * Moderate or severe hepatic impairment, liver enzymes greater than 3 times the upper limit of normal, or Child-Pugh class B or C. * Estimated glomerular filtration rate below 30 mL/min/1.73 m². * Concomitant use of drugs that substantially affect rosuvastatin pharmacokinetics and cannot be temporarily discontinued, including cyclosporine, gemfibrozil, or potent OATP1B1/BCRP or CYP2C9 inhibitors. * Systemic antibiotic use within 3 months or probiotic, prebiotic, or synbiotic use within 4 weeks before sampling. * Continuous current rosuvastatin or other statin therapy unless medically discontinued with an adequate washout period under physician supervision. * Clinically relevant baseline hypotension, significant hyperkalemia, renal impairment, or another condition that makes a losartan test dose unsafe. * Severe postoperative complication preventing oral dosing, including active gastrointestinal leak, intractable vomiting, or severe anastomotic stenosis. * Pregnancy. Participants of childbearing potential undergo routine preoperative beta-hCG testing.

Treatments and study arms

Rosuvastatin

Drug

Rosuvastatin 10 mg tablet, single oral dose at each of two pharmacokinetic visits. Other name: rosuvastatin calcium.

Losartan (Control)

Drug

Losartan 25 mg tablet, single oral dose at each of two pharmacokinetic visits. Other name: losartan potassium.

Primary outcomes

Change in rosuvastatin area under the plasma concentration-time curve extrapolated to infinity (AUC0-infinity)Within 30 days before surgery and approximately 12 weeks after surgery (postoperative visit may be delayed up to 6 months for clinical safety).

Individual rosuvastatin AUC0-infinity will be estimated from plasma concentrations at 0, 1.5, and 4 hours using maximum a posteriori Bayesian estimation based on a published population pharmacokinetic model. Within-participant postoperative/preoperative geometric mean ratios and between-procedure differences will be estimated.

Change in losartan area under the plasma concentration-time curve extrapolated to infinity (AUC0-infinity)Within 30 days before surgery and approximately 12 weeks after surgery (up to 6 months if delayed for clinical safety).

Individual losartan AUC0-infinity will be estimated using the same sparse-sampling MAP Bayesian strategy and a published parent-metabolite population model.

Study locations

1 locations were listed when this page was built. The first 40 are shown.

Hospital das Clínicas, Ribeirão Preto Medical School, University of São Paulo🇧🇷 Ribeirão Preto, São Paulo, Brazil

Open map

Fabiana CP Valera, MD PhDContact

Email · Call +5516981548312